Peringkat dalam Saham
#25851
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing... Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, an RSV-targeted vaccine currently undergoing Phase 1/1b clinical trials; IVX-A12, a bivalent candidate designed to target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV); IVX-241, a candidate specifically designed for hMPV; and IVX-411, a SARS-CoV-2 vaccine based on a receptor binding domain (RBD) sequence antigen, which is also in Phase 1/2 clinical trials. Established in 2017, Icosavax maintains its corporate headquarters in Seattle, Washington.
Harga Saham
$15.31
Terakhir disinkronkan: 2024-02-29
Kapitalisasi Pasar
$45.70M
Perubahan (1 tahun)
0.00%
Perdagangan Icosavax, Inc. (ICVX)
Harga ICVX dengan kapitalisasi pasar B
Kapitalisasi pasar dari Icosavax, Inc.(ICVX)
Kapitalisasi Pasar: $45.70M
Per August 2026, Icosavax, Inc. memiliki kapitalisasi pasar sebesar $45.70M. Ini menjadikan Icosavax, Inc. sebagai perusahaan 25851st paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Icosavax, Inc. dari 2021 hingga 2026
ICVX dibandingkan dengan 5 teratas stocks paling populer
| Harga ICVX |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.257T
|
+11,501,961.75%
|
|
|
|
|
$4.599T
|
+10,061,812.56%
|
|
|
|
|
$4.107T
|
+8,985,159.26%
|
|
|
|
|
$3.577T
|
+7,826,978.55%
|
|
|
|
|
$2.807T
|
+6,142,321.87%
|
